Millbrae, California — According to state and local development sources, Eikon Therapeutics Inc. plans to invest $350,700,000.00 to build out new space in Millbrae. The company plans to occupy the new space in Millbrae, on or about May 1, 2027. According to the company website Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikons discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikons landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikons drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies. Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines.

To learn more about Eikon Therapeutics Inc., visit http://www.eikontx.com/

Company Contact:
Roger Perlmutter, Chief Executive Officer
341-777-0566

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.